Objective-We investigated the impact of several genetic variants located in genes encoding for proteins involved in biogenesis, maturation, and intravascular remodeling of high density lipoprotein (HDL) particles on plasma efflux capacity. Approach and Results-The capacity of whole-plasma to mediate cholesterol efflux from cholesterol-loaded human THP-1 macrophages was measured in 846 individuals (450 men and 396 women). We demonstrated that rs17231506 (CETP c.-1337 C>T), rs2230806 (ABCA1 p.R219K), rs1799837 (APOA1 c.-75 G>A), rs5086 (APOAII c.-265 T>C), and rs1800588 (LIPC c.-514 C>T) single nucleotide polymorphisms (SNPs) significantly modulate the capacity of whole-plasma to mediate cholesterol efflux from human macrophages in a sex-dependent manner. Such associations were independent of circulating plasma lipid levels (HDL-cholesterol, triglyceride, low density lipoprotein-cholesterol). In women, we identified the APOA1 c.-75 G>A and the LIPC c.-514 C>T variants as major contributors of interindividual variability of plasma efflux capacity, whereas the ABCA1 p.R219K and the APOAII c.-265 T>C SNPs mostly contribute to total variance of plasma efflux capacity in men. Multiple regression analyses revealed that the 7 SNPs tested accounted together for approximately 6% of total plasma efflux capacity. We demonstrated that genetically determined plasma efflux capacity represents a better predictor of macrophage cholesterol removal, as compared with plasma HDL-cholesterol levels. Conclusions-Genetic variants located within genes encoding proteins involved in HDL metabolism significantly impact plasma efflux capacity independently of variation in plasma HDL-cholesterol levels. (Arterioscler Thromb Vasc Biol. 2013;33:822-828.) Key Words: cholesterol efflux ◼ high density lipoprotein ◼ macrophages ◼ single nucleotide polymorphisms
E pidemiological studies have identified elevated plasma high density lipoprotein-cholesterol (HDL-C) levels as a protective factor against premature atherosclerosis and coronary artery disease. 1 It is well established that genetic factors largely contribute to interindividual variability of plasma HDL levels and account for 40% to 60% of such variation. 2 During the last decade, many single nucleotide polymorphism (SNP) association studies have been conducted to understand genetic determination of plasma lipids levels, including HDL-C variability. [3] [4] [5] Determinant genes involved in HDL metabolism are those coding for apolipoproteins, enzymes, lipid transfer proteins, and cellular receptors or transporters. Many genetic variant have been identified on genes encoding for proteins involved in biogenesis (APOA1 and ABCA1), 6 maturation (ABCG1 and APOAII), 7, 8 and intravascular remodeling (CETP and LIPC) 9,10 of HDL particles.
In particular, significant associations between genetic variants and plasma HDL-C levels, and more importantly, atherosclerosis progression or cardiovascular risk and with quantitative and qualitative features of HDL subspecies have been demonstrated. Numerous studies have demonstrated that rs1799837 (APOA1 c.-75 G>A) SNP is associated with higher plasma HDL-C levels 11 in carriers of the AA genotype. The rs2230806 (ABCA1 p.R219K) SNP has been reported to be associated with HDL-C and the severity of atherosclerosis. 12 The K219 allele is associated with higher plasma HDL-C and small HDL particle levels, and is proposed to be an antiatherogenic allele. 13 The functional rs5082 (APOAII c.-265 T>C) SNP has been shown to be associated with coronary artery disease risk. 14 Moreover , the rs1378577 (ABCG1 c.-134 T>G) SNP has been shown to modulate transcriptional activity of the human ABCG1 gene and was reported to be associated with plasma HDL-C levels in some studies, but not in others. 15 The rs708272 (CETP TaqIB) SNP identified in the first intron of the CETP gene is associated with plasma CETP concentration, HDL-C levels, and HDL particle size. 13, 16 However, the rs708272 SNP does not represent a functional regulatory site by itself but is a marker for other functional sites, such as the rs17231506 (CETP c.-1337 C>T) SNP. 17 Equally, it has been demonstrated that the rs1800588 (LIPC c.-514 C>T) SNP in the hepatic lipase gene promoter is associated with significant variations in plasma HDL2-C levels and HDL particle size with the T variant associated with higher HDL-C concentrations as a result of an increase in the large HDL subfraction. 18 Despite the well-established protective role of HDL particles against cardiovascular disease, many recent studies fail to identify clear relationships between genetic determinant of HDL-C particles and cardiovascular disease, 19 thus suggesting that HDL function rather than HDL levels might underlie the atheroprotective role of HDL. 20 In particular, determinant contribution of HDL to cardiovascular benefit is intimately linked to their role in cellular cholesterol efflux process, which represents a key step in atherosclerosis development by preventing lipid accumulation in macrophages, and thus, foam cell formation. 21 The importance of HDL efflux functionality has been recently reported by Khera et al, 22 showing a significant inverse relationship between HDL-C efflux capacity and cardiovascular risk or atherosclerosis development, independently of HDL-C levels.
HDL-mediated cholesterol efflux from macrophages represents a major atheroprotective mechanism. However, it has been demonstrated that apolipoprotein B-containing lipoprotein particles equally contribute to cholesterol efflux from human macrophages as result of a continuous transfer of cholesterol from HDL to apolipoprotein B-containing lipoproteins, which maintains efficient HDL-mediated cellular cholesterol efflux. 23, 24 Genetic variants localized on genes encoding for key proteins involved in HDL metabolism, including those presently studied, are equally associated with both quantitative and qualitative modifications of apolipoprotein B-containing lipoproteins. 25 This highlights that evaluation of macrophage cholesterol efflux by using whole-plasma represent a more potent physiological approach as compared with HDL isolated by precipitation. We thus presently studied the impact of various genetic variants located in genes involved in HDL metabolism on the capacity of whole-plasma to mediate cholesterol efflux from human foam cells.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Plasma Lipid and Clinical Characteristics of the Study Population
As shown in Table 1 , no significant difference in mean age, body mass index, fasting blood glucose, plasma low density lipoprotein-cholesterol (LDL-C), and apolipoprotein B levels, as well as in plasma CETP activity or concentration was observed between men and women. By contrast, women displayed significant increase in plasma levels of total cholesterol (+4.8%; P=0.005), HDL-C (+26.7%; P=0.001), and apoA-I (11.7%; P=0.002), associated with a concomitant reduction in plasma triglyceride (TG) levels (-23%; P=0.001) as compared with men.
Genotype distribution and allele frequencies did not significantly differ between men and women (χ 2 test >0.05; see Table II in the online-only Data Supplement. Relationships between genetic variants and plasma lipid and apoliporotein levels are presented in Tables III and IV in 
Impact of Individual Genetic Variants on Cholesterol Efflux From Human Macrophages
The impact of each SNP on the capacity of whole-plasma to mediate cholesterol efflux from cholesterol-loaded THP-1 macrophages between genotypes is presented in Table 2 . We observed that CETP c. -1337 C>T, LIPC c. -514 C>T, APOAI c. -75 G>A, ABCA1 p.K219R, and APOAII c. -265 T>C SNPs were associated with a significant modification of plasma efflux capacity in a sex-dependent manner. By contrast, no significant impact of the CETP TaqIB or the ABCG1 c. -134 T>G SNPs on the overall capacity of total plasma to mediate cholesterol efflux from human macrophages was detected.
The CETP c. -1337 C>T SNP appeared to be significantly associated with plasma efflux capacity specifically in men subjects, when regression analysis was performed using a recessive model. Indeed, a significant reduction (-12.1%; P<0.003) in the overall capacity of total plasma to mediate cholesterol efflux from human macrophage was observed in men carrying the TT genotype for the CETP c. -1337 C>T SNP as compared with those carrying the C allele ( Figure 1A) . Similarly, plasmas from men with the AA genotype for ABCA1 p.K219R displayed a significant increased capacity (+16.1%; P=0.001) to mediate cholesterol efflux from human macrophages as compared with those carrying the G allele ( Figure 1B ). In addition, by using a dominant model, we observed that men carrying the C allele for APOAII c. -265 T>C variant displayed a significant increase (+9%; P=0.005) in plasma efflux capacity in comparison with those carrying the TT genotype ( Figure 1C ).
We equally observed a significant increase in plasma efflux capacity in women carrying the less frequent genotypes for either the LIPC c. -514 C>T (+8.6%; P=0.004) or the APOAI c. -75 G>A (+14.3%; P=0.005) SNPs as compared with those carrying the most frequent alleles ( Figure 1D and 1E). By contrast, no significant relationship was detected between these 2 latter genetic variants and plasma efflux capacity in men ( Table 2) .
The studied population was composed of hypertriglyceridemic subjects (25%), and involved ≈40% of patients receiving a lipid-lowering therapy. It is relevant to note that the impact of LIPC c. -514 C>T, APOAI c. -75 G>A, CETP c. -1337 C>T, and ABCA1 p.K219R variants on plasma efflux capacity was not related to plasma TG levels. By contrast, the impact of APOAII c. -265 T>C SNP on plasma efflux capacity was primarily observed in subjects with elevated plasma TG levels, and thus, probably to the presence of very low density lipoprotein particles. We observed that the effect of CETP c.
-1337 C>T and APOAI c. -75 G>A on plasma efflux capacity was in significant interaction with lipid-lowering therapy (see the Results in the online-only Data Supplement).
We thus conclude that 5 distinct genetic variants located on key genes involved in HDL biogenesis, intravascular maturation, and remodeling significantly modulate the capacity of whole-plasma to mediate cholesterol efflux from human macrophages in a sexdependent manner (ie, CETP c. -1337 C>T, ABCA1 p.K219R, and APOAII c. -265 T>C SNPs in men and APOAI c. -75 G>A and LIPC c. -514 C>T SNPs in women). It is relevant to note that the impact of each SNP on the capacity of whole-plasma to mediate cholesterol efflux from macrophages was evaluated after adjustment for circulating HDL-C, LDL-C, and TG levels, and of other modifiable factors, such as physical exercise, alcohol consumption, smoking, body mass index, lipid-lowering therapy, and use of contraceptive treatment or estrogen replacement therapy for women (Model 1), as well as without adjustment for plasma lipid levels (Model 2). The 2 models reveal similar relationships between SNP and plasma efflux capacity, indicating that the observed relationships between genetic variant and plasma efflux capacity were independent of plasma lipid levels. #Value result from multiple linear regression models after adjustment for age, body mass index, lipid-lowering therapy, alcohol consumption, smoking, physical activity practice, use of contraceptive treatment, or estrogen replacement therapy for women and HDL-C, LDL-C, and TG plasma levels (Model 1) or without adjustment for plasma lipids (Model 2).
†Indicates significant association after bonferroni correction.
Proportion of Plasma Efflux Capacity Variance Explained by Genetic Variants
To determine the global impact of the 7 presently studied SNPs on plasma efflux capacity, we performed regression analyses including all genetic variants as predictive variables and relative plasma efflux capacity as predicted variable. Proportion of plasma efflux capacity variance explained by the model (R 2 ) as well as the relative contribution (r²) of each SNP is presented in Figure 2 . We observed that the 7 presently studied genetic variants contribute together to 6.3% of the plasma efflux capacity (P=0.002) in men (Figure 2, left Table V in the online-only Data Supplement, additional multivariate regression analyses including plasma lipid levels as covariates revealed that, in men, plasma HDL-C levels accounted for 1.19% of the variability of plasma efflux capacity, whereas LDL-C or TG plasma levels did not represent independent significant modulators of plasma efflux capacity. In comparison, the proportion of plasma efflux variance explained by ABCA1 p.K219R, APOAII c. -265 T>C, and CETP c. -1337 C>T SNPs was of 2.85%, 2.31%, and 0.82%, respectively. By contrast, in women, TG and HDL-C plasma levels represented significant predictive modulators of plasma efflux capacity accounting for 2.74% and 2.18% of plasma efflux variability. In comparison, LIPC c. -514 C>T and APOAI c. -75 G>A SNPs were responsible for 2.34% and 2.37% of plasma efflux capacity variability, respectively. These observations clearly indicate that the impact of a single genetic variant on variability of plasma efflux capacity is of the same magnitude than that of plasma lipid levels.
To further explore the contribution of genetic variant on interindividual variability of plasma efflux capacity, we performed efflux-gene score and HDL-C-gene score, as described in the Methods in the online-only Data Supplement. The impact of plasma HDL levels, HDL-C-gene score, and efflux-gene score on plasma efflux capacity is presented in Table 3 . Interestingly, despite the fact that plasma HDL-C levels were significantly associated with plasma efflux capacity; variation of plasma HDL-C levels conferred by genetic score was not. Our present study reveals that efflux-genetic score represents a relevant predictor of interindividual variability of plasma efflux capacity.
Discussion
For the first time, we demonstrate that genetic variants located within human genes encoding key proteins involved in HDL metabolism impact significantly the interindividual variability of plasma capacity to mediate cholesterol efflux from human These observations are entirely consistent with the fact that sex hormones regulate many genes involved in intravascular HDL metabolism, leading to higher HDL-C levels in women as compared with men, 26 and modulating the intrinsic capacity of circulating HDL particles to mediate cellular-free cholesterol efflux. 27 In this context, it is relevant to consider that we presently identified sex as a strong and independent determinant of plasma efflux capacity (Table VI in the online-only Data Supplement). It is thus likely that sex-specific impact of genetic variants on plasma efflux capacity results from differential hormonal regulation of gene expression, and consequently from circulating levels and activities of the corresponding proteins, as well as from distinct quantitative and qualitative features of HDL particles between men and women.
Contrasting data have been reported by others, indicating either unaltered 28, 29 or increased 30, 31 plasma HDL-C levels in subjects carrying the AA genotype for the APOA1 c. -75 G>A or the ABCA1 pR219K SNPs as compared with those carrying the most frequent allele for these 2 genetic variants. The present study reveals no significant association between the APOA1 c. -75 G>A or the ABCA1 pR219K SNPs and plasma HDL-C levels, suggesting that their impact on plasma efflux capacity might primarily result from structural modification of HDL particles. In good agreement with our data, earlier studies have reported that subjects carrying less frequent alleles of both the APOA1 c. -75 G>A or the ABCA1 pR219K SNPs displayed increased circulating levels of small HDL particles, which may account for the presently described improvement of plasma cholesterol efflux capacity. 13, 32, 33 The role of ApoAII in cholesterol efflux has been described using transgenic mice. In particular, serum from mice overexpressing human APOAII gene displayed a reduced capacity to stimulate cellular cholesterol efflux as compared with those from control mice. 34, 35 In the present study, men carrying the less frequent allele for the APOAII c.-265 T>C SNP, known to be associated with a reduced transcriptional activity of the human APOAII gene, displayed a significant higher plasma efflux capacity than those carrying the TT genotype. Consistent with animal studies, such observation strongly suggests that a reduction in circulating levels of ApoAII-containing HDL particles result in an increased capacity of plasma to mediate efflux from macrophages. In addition, it is likely that such impact may account for the reduction of coronary artery disease risk that has been recently reported in men carrying the CC genotype. 14 It has been previously demonstrated that less frequent alleles for either rs1800588 (LIPC c. -514 C>T) or rs17231506 (CETP c. -1337 C>T) SNPs are associated with lower transcriptional activity of the respective gene promoters, resulting in significant reductions of circulating protein levels and activities. 17, 36 We observed that women carrying the TT genotype for the LIPC c. -514 C>T SNP displayed an enhanced plasma efflux β regression coefficients were obtained after adjustment for age, body mass index, smoking, alcohol consumption, physical activity practice, lipid-lowering therapy, use of contraceptive treatment, or estrogen replacement therapy for women and LDL-C, TG plasma levels. For efflux-gene score further adjustment for HDL-C was included.
#Plasma HDL-C levels were included as predictive variable. †HDL-C-gene score or efflux-gene score were included as predictive variables.
capacity, despite a lack of significant effect on HDL-C plasma levels. These observations led us to suggest that the relationship between LIPC c. -514 C>T SNP and plasma efflux efficiency might be primarily related to intrinsic HDL structure and function. 27 By contrast, elevated plasma HDL-C levels in men carrying the less frequent allele for the CETP c. -1337 C>T SNP was associated with a reduced ability of plasma to mediate cholesterol efflux from human macrophages. Similar conclusions were reached by Borggreve et al, 37 who observed that the functional rs1800775 (CETP c. -629 C>A) variant, which is equally associated with an increase in circulating levels of HDL-C 38 and in strong linkage disequilibrium with the CETP c. -1337 C>T SNP, 17 was associated with a decreased capacity of plasma to mediate cellular efflux from fibroblasts. 37 Multiple regression models used in the present study revealed that the 7 SNPs tested explain ≈6% of the plasma efflux variability. Such genetic impact on plasma efflux capacity might appear quite low. However, these observations are entirely consistent with previous Genome Wide Association Studies, which revealed that genetic variation explained no more than 10% of the total variance of HDL particle size or HDL-C levels. 25, 39 This reflects the complexity of HDL metabolism, which is largely polygenic involving various regulatory pathways, and which is also strongly influenced by environmental factors.
In conclusion, our present study demonstrates that genetic variants associated with plasma efflux capacity differ from those previously identified as major modulators of circulating HDL-C levels. 40 This observation clearly supports that the contention by which SNPs located on genes encoding for key proteins involved in HDL metabolism, that is, ABCA1, APOA1, CETP, and LIPC, affect cardiovascular disease through their impact on HDL-C levels can be challenged. 28, [41] [42] [43] In good agreement with this observation, a very recent mendelian randomization study demonstrated that increase in plasma HDL-C levels as a function of genetic score was not significantly associated with the expected reduction of risk of myocardial infarction, highlighting the limitation of plasma HDL-C levels as the optimal marker for evaluation of cardiovascular risk and the need to dispose of a clinical tool to evaluate HDL functionality. 19 Interestingly, alleles of 5 SNPs, presently identified as associated with an increased plasma efflux capacity, were also associated with a reduced risk of coronary heart disease in several studies. 14, 30, [44] [45] [46] Although this finding remains to be confirmed, it strongly suggests that plasma efflux capacity might be a key factor in coronary heart disease risk. A major limitation of our present study is that evaluation of plasma efflux capacity represents an estimation of the efficacy of the initial step of the reverse cholesterol transport pathway, and thus cannot be transposed to an evaluation of global reverse cholesterol transport in vivo, as fecal cholesterol excretion has not been measured. Evaluation of plasma efflux capacity in largescale studies is now required to better understand metabolic and regulatory pathways affecting the ability of plasma to mediate cholesterol efflux from human macrophages and their association with cardiovascular disease. For that purpose, efflux assay, which is presently quite cumbersome, needs to be standardized and adapted for high-throughput analyses. Finally, our study provides evidences that genetic background of patients should be considered during evaluation of clinical efficacy and cardiovascular benefit of pharmacological agents targeting HDL. 33, 47 
